Similar articles

• Challenges in the management of invasive pulmonary zygomycosis: the Alfred experience.

  Saxena P, Shen SH, Morrissey O, Gooi JH. Saxena P, et al. ANZ J Surg. 2015 Oct;85(10):700-1. doi: 10.1111/ans.13264. ANZ J Surg. 2015. PMID: 26429509 No abstract available.
• Lipid-based amphotericin in pulmonary zygomycosis: safety and efficacy of high exposure in a renal allograft recipient.

  Crompton JA, Alexander D, Somerville T, Shihab FS. Crompton JA, et al. Transpl Infect Dis. 2004 Dec;6(4):183-7. doi: 10.1111/j.1399-3062.2004.00076.x. Transpl Infect Dis. 2004. PMID: 15762937
• Successful treatment of pulmonary zygomycosis in two transplant recipients with liposomal amphotericin B and partial surgical resection followed by posaconazole.

  Cooke DT, Pagani FD, Kaul DR, Cooke KR, Lau CL, Riddell J 4th. Cooke DT, et al. Mycoses. 2010 Mar 1;53(2):163-7. doi: 10.1111/j.1439-0507.2008.01666.x. Epub 2009 Jan 9. Mycoses. 2010. PMID: 19207843 No abstract available.
• Lipid formulations of amphotericin B as first-line treatment of zygomycosis.

  Petrikkos GL. Petrikkos GL. Clin Microbiol Infect. 2009 Oct;15 Suppl 5:87-92. doi: 10.1111/j.1469-0691.2009.02987.x. Clin Microbiol Infect. 2009. PMID: 19754765 Review.
• Zygomycosis and diabetes mellitus.

  Lanternier F, Lortholary O. Lanternier F, et al. Clin Microbiol Infect. 2009 Oct;15 Suppl 5:21-5. doi: 10.1111/j.1469-0691.2009.02975.x. Clin Microbiol Infect. 2009. PMID: 19754752 Review.